Human trials, safety signals, dosing and the limits of what we know.
TL;DR: NMN and related NAD+ precursors reliably raise NAD+ levels in humans, and short-term trials show modest improvements in some metabolic and vascular markers. No completed human trial has shown that NMN extends lifespan, and long-term safety data are still limited. In the UK it remains a food supplement, not a medicine.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme used in hundreds of cellular reactions, from mitochondrial energy production to DNA repair and sirtuin signalling. NAD+ levels decline with age in most tissues, and this drop has been linked to metabolic dysfunction, reduced mitochondrial activity and impaired stress responses.
The theory behind NAD+ precursors is simple: if ageing lowers NAD+, and low NAD+ contributes to age-related decline, then restoring NAD+ might slow some aspects of ageing. The two most studied oral precursors are:
Both raise blood NAD+ in humans. Whether that translates into lasting health benefits is the open question.
Most NMN human data come from small, short trials in middle-aged and older adults. Key observations include:
A 2024 meta-analysis of randomised controlled trials concluded that NMN supplementation improves blood NAD+ and some metabolic outcomes, but emphasised that trials are heterogeneous and longer studies are needed to judge clinical relevance.
Key gap: No published human trial has measured whether NMN users live longer or develop fewer age-related diseases than non-users.
Both precursors raise NAD+, but they are not identical. NR has been tested in larger and longer human trials through the NIAGEN brand and ChromaDex-funded studies. NMN has more mouse longevity data and a larger consumer market, especially since high-profile advocates brought it mainstream.
| Feature | NMN | NR |
|---|---|---|
| Molecular size | Larger (requires conversion) | Smaller (enters cells directly in some models) |
| Human trial volume | Moderate and growing | Larger, especially for safety |
| Longevity mouse data | Stronger in some studies | Positive but more mixed |
| UK availability | Widely sold as food supplement | Widely sold as food supplement |
For most UK buyers, the practical difference is smaller than marketing suggests. Purity, dose and formulation stability matter more than the precursor type.
Across short-term trials, NMN and NR are generally well tolerated. The most commonly reported side effects are mild gastrointestinal symptoms, flushing and headache. Serious adverse events are rare in published studies.
Cautions:
Because NMN is sold as a food supplement in the UK, quality varies. Look for:
๐ Check price on Amazon UK โ NMN
๐ Check price on Amazon UK โ nicotinamide riboside (NR)
Affiliate ID placeholder: replace with Amazon Associates tag once configured.
These sources are referenced inline throughout the article and listed below for full transparency.
"Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." Reports improved walking speed and grip strength.
View DOI"Nicotinamide adenine dinucleotide metabolism and arterial stiffness after chronic nicotinamide mononucleotide supplementation: a multicentre, randomised, double-blind, placebo-controlled trial." Found improved arterial stiffness with NMN plus exercise.
View DOI"Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice." Landmark mouse study showing improved insulin sensitivity, eye function and mitochondrial homeostasis.
View DOI"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Key NR safety and pharmacokinetics study.
View DOI"The efficacy and safety of ฮฒ-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled trial." Reports dose-dependent NAD+ elevation and physical-performance benefits.
View DOI"Nicotinamide mononucleotide supplementation improves sleep quality and reduces fatigue in middle-aged and older adults: a randomized, double-blind, placebo-controlled study." Subjective sleep and fatigue benefits at 300 mg/day.
View DOINo human lifespan trial has been completed. Animal studies suggest NAD+ precursors can improve some markers of metabolic ageing, but it is not proven that NMN extends human lifespan.
NMN and NR are both NAD+ precursors. NR is smaller and crosses cell membranes more easily in some models; NMN is one biochemical step closer to NAD+ and has been more widely studied in rodent ageing models. Human head-to-head data comparing long-term effects remain limited.
Short-term human trials at doses up to 900โ1,200 mg/day have reported few serious adverse events. Long-term safety data beyond one to two years are sparse. People with liver or kidney disease, those on medication, and pregnant or breastfeeding women should avoid NMN unless a clinician says otherwise.
The FDA determined in 2022 that NMN was being investigated as a new drug, which in the US can remove it from the dietary-supplement category. This is a US regulatory decision and does not apply in the UK, where NMN remains available as a food supplement sold under food-safety rules.
Look for third-party testing certificates, purity data, stable salt forms, clear dosing on the label, and a UK-based seller with contact details. Avoid products that make disease-treatment claims.